Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
ConditionAortic Valve Regurgitation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXijing Hospital
About this trial
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
Eligibility criteria
Qualifiers
1. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
2. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form
Disqualifiers
1. Patients who cannot provide informed consent
2. Patients who are treated with TAVR for aortic stenosis
3. Patients who are participating in other clinical trials
Trial design
Treatments tested in this trial
- Transcatheter aortic valve replacement
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov